Endpoints News 生物医药· ENDPOINTS·· 28 天前AI 评分31
Lycia Therapeutics 定价 3.18 亿美元 IPO;Merck sac-TMT 试验提前终止
Lycia's $318M IPO; Merck sac-TMT trial stopped early
AI 导读
Lycia Therapeutics 定价发行 3.175 亿美元首次公开募股(IPO)。Merck 的 sac-TMT 临床试验因未披露原因提前终止。Hexagon Bio、Mineralys Therapeutics 和 Arbor Biotechnologies 的相关新闻因原文被付费墙遮挡,无法提取具体细节。
正文
Plus news about Hexagon Bio, Mineralys Therapeutics and Arbor Biotechnologies.
Lycia prices $317.5 million IPO: Lycia Therapeutics, a company founded by Nobel Prize winner Carolyn …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news